Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy

Host: Charles Turck, PharmD, BCPS, BCCCP <br> Guest: Michael Wang, MD <br> <p>For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex <i>and</i> time sensitive. That’s why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.</p>